FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890732466> ?p ?o ?g. }

• W2890732466 endingPage "69" @default.
• W2890732466 startingPage "51" @default.
• W2890732466 abstract "Background. Retinoblastoma (RB) is a life threatening cancer disease. A breakthrough in the treatment of children with RB is associated with the improvement of conservative treatment that was administered in at least one of the two tumor-affected eyes in most bilateral cases, that was chemotherapy both systemic and local (selective intra-arterial and intravitreal) in most cases combined with laser therapy, cryotherapy, or brachytherapy. The development of such techniques as local chemotherapy is focused on preservation of visual functions, reducing the number of enucleations and radiotherapy (RT) course. The success of the healing of RB is closely associated with a multidisciplinary approach to diagnosis and treatment, as well as specialized longterm follow-up clinical examination. Objective. eye and vision preservation against large intraocular tumors with different growth types and localization without the course of remote radiation therapy was the main purpose. Methods. In the period from September 2012 to January 2016, the study enrolled 45 patients with RB when at least one eye had intraocular tumor spread corresponding to the group C or D. According to the ABC international classification, patients have a relatively good prognosis for organ-preserving treatment. 4 of 18 children with bilateral RB had undergone primary enucleation of worse eye the worst eye, group E; 49 (77.8%) of the 63 affected eyes had features for groups C and D. In this study, no patient received local chemotherapy initially, only after prior systemic chemotherapy. Selective intra-arterial chemotherapy (SIAC) was applied to 41 patients (45 eyes; mean course number was 2), and 32 patients (34 eyes) had undergone intravitreal chemo therapy (IViC) (mean course number was 2). Focal therapy and local chemotherapy were the main methods of treatment for progression (new lesions on the retina) in 8 (16.3%) of 49 eyes with tumors of group C (n=1) and D (n=7); the relapse in 14 of 49 (new lesions on the retina) in eyes with tumors of group C (n=5) and D (n=6) and (new lesions on the retina and the vitreous) in eyes with tumors of group D (n=3) (28.5%), and stabilization of disease n=23 (46.9%). We should note that 2 patients underwent repeated course of in case of systemic chemotherapy, 1 patient — a Gamma Knife procedure due to registered disease stabilization, progression or relapse. Results. 10 (20.4%) of 49 eyes saved due to the combined chemotherapy. In 45 patients diseasefree survival rate was 56.1±8.9 % (with mean follow-up period 26.9±2.5 months). 1 of 45 patients died from leukemia. 44 of 45 patients are alive without metastasis. The mean follow-up was 20 months (3 to 43 months). Eye salvage rate in group C — 14 (93.3%) of 15, in group D — 31 (91.2%) of 34. Conclusion. These methods: second line of systemic chemotherapy, RT, and a Gamma Knife procedure should be considered as a failure of primary treatment. Our study demonstrated a high efficacy of local chemotherapy with promissing techniques of conservation therapy, which safety increases due to experience." @default.
• W2890732466 created "2018-09-27" @default.
• W2890732466 creator A5005449501 @default.
• W2890732466 creator A5006814643 @default.
• W2890732466 creator A5009084160 @default.
• W2890732466 creator A5014855174 @default.
• W2890732466 creator A5015740304 @default.
• W2890732466 creator A5017555223 @default.
• W2890732466 creator A5019887331 @default.
• W2890732466 creator A5033083063 @default.
• W2890732466 creator A5047533225 @default.
• W2890732466 creator A5047697863 @default.
• W2890732466 creator A5054720360 @default.
• W2890732466 creator A5069500434 @default.
• W2890732466 creator A5071834259 @default.
• W2890732466 creator A5077358395 @default.
• W2890732466 creator A5085404846 @default.
• W2890732466 creator A5085737575 @default.
• W2890732466 creator A5089402382 @default.
• W2890732466 date "2018-04-20" @default.
• W2890732466 modified "2023-09-26" @default.
• W2890732466 title "A New Era of Organ-Preserving Treatment in Pediatric Intraocular Retinoblastoma in Russia: A Multicenter Cohort Study" @default.
• W2890732466 cites W10347719 @default.
• W2890732466 cites W1964341502 @default.
• W2890732466 cites W1972912013 @default.
• W2890732466 cites W1979271037 @default.
• W2890732466 cites W1980760089 @default.
• W2890732466 cites W1995509840 @default.
• W2890732466 cites W2008373592 @default.
• W2890732466 cites W2009934230 @default.
• W2890732466 cites W2018066218 @default.
• W2890732466 cites W201820481 @default.
• W2890732466 cites W2063881466 @default.
• W2890732466 cites W2067611128 @default.
• W2890732466 cites W2076338398 @default.
• W2890732466 cites W2077858999 @default.
• W2890732466 cites W2080876378 @default.
• W2890732466 cites W2085681300 @default.
• W2890732466 cites W2095468700 @default.
• W2890732466 cites W2108808305 @default.
• W2890732466 cites W2112934711 @default.
• W2890732466 cites W2125992147 @default.
• W2890732466 cites W2136154953 @default.
• W2890732466 cites W2136400910 @default.
• W2890732466 cites W2142480746 @default.
• W2890732466 cites W2142761201 @default.
• W2890732466 cites W2156502725 @default.
• W2890732466 cites W2161896011 @default.
• W2890732466 cites W2167497727 @default.
• W2890732466 cites W2168914937 @default.
• W2890732466 cites W2618832805 @default.
• W2890732466 doi "https://doi.org/10.15690/onco.v5i1.1866" @default.
• W2890732466 hasPublicationYear "2018" @default.
• W2890732466 type Work @default.
• W2890732466 sameAs 2890732466 @default.
• W2890732466 citedByCount "11" @default.
• W2890732466 countsByYear W28907324662020 @default.
• W2890732466 countsByYear W28907324662021 @default.
• W2890732466 countsByYear W28907324662022 @default.
• W2890732466 crossrefType "journal-article" @default.
• W2890732466 hasAuthorship W2890732466A5005449501 @default.
• W2890732466 hasAuthorship W2890732466A5006814643 @default.
• W2890732466 hasAuthorship W2890732466A5009084160 @default.
• W2890732466 hasAuthorship W2890732466A5014855174 @default.
• W2890732466 hasAuthorship W2890732466A5015740304 @default.
• W2890732466 hasAuthorship W2890732466A5017555223 @default.
• W2890732466 hasAuthorship W2890732466A5019887331 @default.
• W2890732466 hasAuthorship W2890732466A5033083063 @default.
• W2890732466 hasAuthorship W2890732466A5047533225 @default.
• W2890732466 hasAuthorship W2890732466A5047697863 @default.
• W2890732466 hasAuthorship W2890732466A5054720360 @default.
• W2890732466 hasAuthorship W2890732466A5069500434 @default.
• W2890732466 hasAuthorship W2890732466A5071834259 @default.
• W2890732466 hasAuthorship W2890732466A5077358395 @default.
• W2890732466 hasAuthorship W2890732466A5085404846 @default.
• W2890732466 hasAuthorship W2890732466A5085737575 @default.
• W2890732466 hasAuthorship W2890732466A5089402382 @default.
• W2890732466 hasConcept C104317684 @default.
• W2890732466 hasConcept C118487528 @default.
• W2890732466 hasConcept C141071460 @default.
• W2890732466 hasConcept C185592680 @default.
• W2890732466 hasConcept C188261085 @default.
• W2890732466 hasConcept C2776577112 @default.
• W2890732466 hasConcept C2776694085 @default.
• W2890732466 hasConcept C2777416452 @default.
• W2890732466 hasConcept C2780149145 @default.
• W2890732466 hasConcept C509974204 @default.
• W2890732466 hasConcept C55493867 @default.
• W2890732466 hasConcept C71924100 @default.
• W2890732466 hasConceptScore W2890732466C104317684 @default.
• W2890732466 hasConceptScore W2890732466C118487528 @default.
• W2890732466 hasConceptScore W2890732466C141071460 @default.
• W2890732466 hasConceptScore W2890732466C185592680 @default.
• W2890732466 hasConceptScore W2890732466C188261085 @default.
• W2890732466 hasConceptScore W2890732466C2776577112 @default.
• W2890732466 hasConceptScore W2890732466C2776694085 @default.
• W2890732466 hasConceptScore W2890732466C2777416452 @default.
• W2890732466 hasConceptScore W2890732466C2780149145 @default.

• next